Free Trial
NYSE:NVS

Novartis Q2 2025 Earnings Report

Novartis logo
$121.06 +0.04 (+0.03%)
Closing price 07/14/2025 03:59 PM Eastern
Extended Trading
$122.03 +0.97 (+0.80%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis EPS Results

Actual EPS
N/A
Consensus EPS
$2.37
Beat/Miss
N/A
One Year Ago EPS
N/A

Novartis Revenue Results

Actual Revenue
N/A
Expected Revenue
$13.94 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novartis Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 17, 2025
Conference Call Time
1:00AM ET

Conference Call Resources

Novartis Earnings Headlines

Novartis (NVS) Projected to Post Earnings on Thursday
Why Novartis Is Still A 'Buy' After 15% Surge
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Novartis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novartis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novartis and other key companies, straight to your email.

About Novartis

Novartis (NYSE:NVS) International AG, traded on the New York Stock Exchange under the symbol NVS, is a global healthcare company headquartered in Basel, Switzerland. Formed in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has a rich heritage in science and innovation that spans more than 175 years. The company’s mission is to discover new ways to improve and extend people’s lives, drawing on a diverse portfolio of healthcare offerings and a commitment to research and development.

Novartis operates primarily through two major divisions: Innovative Medicines and Sandoz. Innovative Medicines focuses on patented prescription drugs across key therapeutic areas including oncology, immunology and dermatology, neuroscience, and cardiovascular and metabolic diseases. Through its Sandoz division, Novartis is a leader in generic pharmaceuticals and biosimilars, providing more affordable versions of branded medicines and expanding patient access around the world. The company also invests in advanced therapy platforms such as cell and gene therapies, aiming to address complex diseases with novel treatment modalities.

With a presence in over 140 countries, Novartis maintains a broad geographic footprint that encompasses research facilities and manufacturing sites across North America, Europe, Latin America, Asia and Africa. The company’s global reach is supported by strategic partnerships, regional research collaborations and patient access programs designed to tailor therapies to local healthcare needs. Novartis has cultivated a network of academic and industry alliances to accelerate the translation of scientific discoveries into approved medicines.

Under the leadership of Chief Executive Officer Vas Narasimhan, Novartis has emphasized digital transformation, data-driven decision-making and sustainability in its operations. The company’s senior management team brings expertise in scientific research, commercialization and global health policy, guiding a pipeline of assets that underscore Novartis’s commitment to innovation. Through disciplined portfolio management and a focus on patient-centric solutions, Novartis continues to shape the future of medicine on a worldwide scale.

View Novartis Profile

More Earnings Resources from MarketBeat